[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492495":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":34,"responsibleParty":94,"collaborators":20,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":20,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":20,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"Sino Medical Sciences Technology Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Percutaneous transluminal angioplasty and stenting","EXPERIMENTAL","All patients will be implanted with Drug-Eluting Stents (NOVA DES).",[13],"Device: Drug-Eluting Stents",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Drug-Eluting Stents","The NOVA stent is a sirolimus-eluting stent system designed for intracranial artery stenosis with a rapid exchangeable balloon",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Zhongrong Zhongrong","Beijing Tiantan Hospital","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Zhongrong Miao, MD","CONTACT","+8613601243293","zhongrongm@163.com",{"name":33,"role":29,"phone":20,"phoneExt":20,"email":20},"Baixue Jia, MD",[35,50,61,72,83],{"facility":36,"status":37,"city":38,"state":20,"zip":20,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"First People's Hospital of Chenzhou","RECRUITING","Chenzhou","China","CN",{"type":42,"coordinates":43},"Point",[44,45],113.03333,25.8,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":20,"phoneExt":20,"email":20},"Xiaoxi Yao",{"facility":51,"status":37,"city":52,"state":20,"zip":20,"country":39,"countryCode":40,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Ganzhou People's Hospital","Ganzhou",{"type":42,"coordinates":54},[55,56],114.9326,25.84664,{"lat":56,"lon":55},[59],{"name":60,"role":29,"phone":20,"phoneExt":20,"email":20},"Guoyong Zeng",{"facility":62,"status":37,"city":63,"state":20,"zip":20,"country":39,"countryCode":40,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Jinhua Municipal Central Hospital","Jinhua",{"type":42,"coordinates":65},[66,67],119.64421,29.10678,{"lat":67,"lon":66},[70],{"name":71,"role":29,"phone":20,"phoneExt":20,"email":20},"Xiang Bao",{"facility":73,"status":37,"city":74,"state":20,"zip":20,"country":39,"countryCode":40,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"The First Affiliated Hospital of Ningbo University","Ningbo",{"type":42,"coordinates":76},[77,78],121.54945,29.87819,{"lat":78,"lon":77},[81],{"name":82,"role":29,"phone":20,"phoneExt":20,"email":20},"Shengjun Zhou",{"facility":84,"status":37,"city":85,"state":20,"zip":20,"country":39,"countryCode":40,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Shanxi Cardiovascular Hospital","Shanxi",{"type":42,"coordinates":87},[88,89],120.0505,27.66628,{"lat":89,"lon":88},[92],{"name":93,"role":29,"phone":20,"phoneExt":20,"email":20},"Tao Cheng",{"type":95,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100492495","a-registry-study-of-intracranial-atherosclerotic-stenosis-treatment-by-intracranial-drug-eluting-stenting-in-china-100492495",false,"NCT05692882","A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China","To Evaluate the Safety and Efficacy of the NOVA Intracranial Drug-eluting Stent System in \"real World\" Patients with Intracranial Atherosclerotic Stenosis: a Prospective, Multicenter, Post-marketing Registry Clinical Study (NOVA II)","Inclusion Criteria:\n\n1. Males or females between 18 and 80 years of age;\n2. Symptomatic intracranial arteriosclerosis stenosis with reference diameter 2.25-4.00mm;\n3. intracranial artery stenosis ( ≥70%) conformed by digital subtraction angiography (DSA);\n4. Those who voluntarily participate in the study and sign informed consent form.\n\nExclusion Criteria:\n\n1. Those who have surgery within previous 30 days or plan to perform major surgery in the next 90 days (surgery grade 3 and above);\n2. Subjects of acute hemorrhagic stroke within 3 months;\n3. The baseline mRS of disabling stroke is more than 3;\n4. The target vessel is severely calcified and closely related to stenosis;\n5. Non-atherosclerotic diseases (e.g. arterial dissection, Moya Moya disease, vascular inflammatory lesions caused by infection, autoimmune diseases, post-irradiation, postpartum status; developmental or genetic abnormalities such as fibromuscular dysplasia, sickle cell anemia, suspected vasospasm);\n6. It is suspected that the ischemic event is due to embolism or arterial embolism from the extracranial segment (including ipsilateral chest or neck vascular occlusive disease) or potential cardiogenic embolism (e.g. atrial fibrillation, mitral stenosis, patent foramen ovale, left ventricular thrombus, myocardial infarction within 6 weeks, etc.);\n7. Target artery's supplying artery stenosis \\> 50%. For example, patient with middle cerebral artery (MCA) severe stenosis (target artery) and the ipsilateral internal carotid artery (ICA) stenosis \\> 50% should be excluded; patient with basilar artery (BA) severe stenosis (target artery) and the dominant vertical artery (VA) stenosis \\> 50% should be excluded;\n8. There are intracranial tumors, or intracranial arteriovenous malformations;\n9. Those who are allergic to heparin, aspirin, clopidogrel, contrast agents, anesthetics, and stent components;\n10. Pregnant and lactating women\n11. Those who are unable to complete follow-up because of mental illness, cognitive or emotional disorders;\n12. Inapplicable for this study at the investigators' viewpoints.","ALL","18 Years","85 Years",{"count":107,"type":108},1000,"ESTIMATED","INTERVENTIONAL",[111],"NA","The primary objective of this trial is to evaluate the long-term safety and efficacy of the NOVA intracranial drug-eluting stent system in \"real world\" patients with intracranial atherosclerotic stenosis.",[114,115,17,116],"Intracranial Arteriosclerosis","Stenosis Artery","Intracranial Artery Stenosis",[118,119,120],"endovascular therapy","intracranial drug-eluting stent","symptomatic intracranial artery stenosis (sICAS)","2025-03-26",{"date":123,"type":124},"2025-04-01","ACTUAL",{"date":126,"type":124},"2023-11-16",{"date":128,"type":108},"2029-12-30",{"name":5,"class":6},5]